Open AccessClinical characteristics of non‐small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions
Author(s) -
Liu Qinghua,
Huang Qingyan,
Yu Zhikang,
Wu Heming
Publication year - 2022
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.13472
Subject(s) - ros1 , medicine , anaplastic lymphoma kinase , lung cancer , odds ratio , adenocarcinoma , confidence interval , gastroenterology , oncology , tyrosine kinase , cancer , receptor , malignant pleural effusion
Objective To study the relationship between clinical characteristics and anaplastic lymphoma kinase ( ALK ) fusions, c‐ros oncogene 1, receptor tyrosine kinase ( ROS1 ) gene fusions, and epidermic growth factor receptor ( EGFR ) mutations in non‐small cell lung cancer (NSCLC) patients to distinguish these different types. Methods Both ALK , ROS1 gene rearrangements and EGFR mutations testing were performed. The clinical characteristics and associated pulmonary abnormalities were investigated. Results Four hundred fifty‐three NSCLC patients were included for analysis. One hundred seventy (37.5%), 32 (7.1%), and 9 cases (2.0%) with EGFR mutations, ALK gene fusions, and ROS1 gene fusions were identified, respectively. The EGFR ‐positive and ALK&ROS1 ‐positive were more common in female ( χ 2 = 61.934, P < 0.001 and χ 2 = 28.152, P < 0.001), non‐smoking ( χ 2 = 59.315, P < 0.001 and χ 2 = 11.080, P = 0.001), and adenocarcinoma ( χ 2 = 44.864, P < 0.001 and χ 2 = 12.318, P = 0.002) patients; proportion of patients with emphysema was lower ( χ 2 = 35.494, P < 0.001 and χ 2 = 15.770, P < 0.001) than the wild‐type patients. The results of logistic regression analysis indicated that female (adjusted odds ratio [OR] 1.834, 95% confidence interval [CI] 1.069–3.144, P = 0.028), non‐smoking (adjusted OR 2.504, 95% CI 1.456–4.306, P = 0.001), lung adenocarcinoma (adjusted OR 4.512, 95% CI 2.465–8.260, P < 0.001), stage III–IV (adjusted OR 2.232, 95% CI 1.066–4.676, P = 0.033), and no symptoms of emphysema (adjusted OR 2.139, 95% CI 1.221–3.747, P = 0.008) were independent variables associated with EGFR mutations. Young (adjusted OR 3.947, 95% CI 1.873–8.314, P < 0.001) and lung adenocarcinoma (adjusted OR 2.950, 95% CI 0.998–8.719, P = 0.050) were associated with ALK/ROS1 fusions. Conclusions EGFR mutations were more likely to occur in non‐smoking, stage III–IV, and female patients with lung adenocarcinoma, whereas ALK&ROS1 gene fusions were more likely to occur in young patients with lung adenocarcinoma. Emphysema was less common in patients with EGFR mutations.